The 7 Commercial Red Flags PE Firms Miss in Healthcare Deals

Most healthcare deals don't blow up on valuation. They blow up on commercial assumptions nobody tested during diligence.

I've sat on both sides of this table: the operator defending the forecast, and the advisor stress-testing it. The financial diligence is almost always excellent. The commercial diligence is where the expensive surprises hide. Here are the seven I look for first.

1. Founder-led revenue

The top three customer relationships all run through the founder or CEO. The deck calls them "strong customer relationships." I call it key-man risk.

The test: Ask whether the top five accounts would renew if the founder left tomorrow. Then ask who else in the company those customers would call. If the answer is a long silence, discount the retention assumptions.

2. Pipeline theater

The deck shows 3x pipeline coverage. But half the pipeline hasn't had meaningful activity in 90 days, stages are self-reported by reps, and "commit" means "we had a good call."

The test: Re-age every opportunity by last substantive activity, not stage. Then apply the company's own historical stage-to-close conversion rates. The coverage number that survives is the real one. It's usually half the headline.

3. Discounting as a sales strategy

Average realized discount has crept up for six straight quarters. The team calls it "competitive." What it actually means: the value proposition isn't landing, so price is doing the selling.

The test: Look at realized price per unit over eight quarters, not list price. If it's declining while volume grows, you're buying revenue. That trend accelerates the day growth pressure increases post-close.

4. Concentration hiding in plain sight

Fifty logos on the slide. But roll the revenue up to the parent entity and five health systems are 60% of it. One lost RFP cycle and the growth plan is fiction.

The test: Always analyze concentration at the ultimate parent level, not the facility or division level. Healthcare consolidates constantly. Last year's diversified book is this year's concentration risk

5. No commercial owner

The CEO is the de facto CRO. There's a VP of Sales with a small team, marketing reports to the CEO, and pricing decisions happen in hallway conversations.

The test: Ask who owns the number post-close and watch the room. If three people point at each other, there's no commercial operating system. There's a founder with helpers. Budget 12 to 18 months and a real leadership hire to build one.

6. "Hire more reps" as the growth plan

The entire growth thesis is adding headcount. No conversion math, no capacity model, no point of view on why the next ten reps will produce what the last ten didn't.

The test: Divide new pipeline created by fully-ramped rep over the last four quarters. If that number doesn't support the hiring plan, the model needs a new motion. New segment, new channel, new product. Not more of the same.

7. Customers who won't advocate

Satisfaction scores look fine. But ask for five reference calls and watch what happens: delays, substitutions, "our policy doesn't allow it." Satisfied customers renew. Only advocates expand, and expansion is where the return lives.

The test: Count completed reference calls, not NPS. Then ask references what they'd change. The gap between the score and the substance tells you everything about net revenue retention risk.

What good commercial diligence looks like

None of these require a six-month engagement. A focused three-week sprint surfaces every one of them: pipeline forensics, pricing archaeology, concentration analysis, and a dozen customer conversations.

You don't get a thicker deck. You get a short list: what has to be true for the investment thesis to hold, and what it costs to make it true.

That's the work I do with PE firms and founders before the ink dries, and in the first 90 days after.

Harborline Growth Advisory helps PE-backed and founder-led healthcare companies determine where the next meaningful growth will come from, then build the commercial engine to capture it. Let's talk.